InvestorsHub Logo

F1ash

07/06/17 8:17 AM

#188988 RE: runninggirl2016 #188985

And here are the numbers from the drug generating 4 Billion (with a B) for UC.

"Patients treated with adalimumab achieved a significantly higher rate of clinical remission than patients receiving placebo both at Week 8 (17% vs 9%; P=.019) and at Week 52 (17% vs 9%; P=.004).

Certainly makes the B 50% CR numbers look impressive even though they are unblinded, and uncontrolled.

georgejjl

07/06/17 8:20 AM

#188991 RE: runninggirl2016 #188985

runninggirl GREAT POST!!!

It is no surprise to us why we have generated significant excitement regarding Brilacidin among patients, health care professionals and potential industry partners interested in this truly novel IBD drug candidate.



http://www.ipharminc.com/new-blog/2017/7/3/growing-interest-in-novel-non-biologic-treatments-for-inflammatory-bowel-disease

Good luck and GOD bless,

George

LilyGDog

07/06/17 8:48 AM

#188994 RE: runninggirl2016 #188985

Thanks Runninggirl! great article. Looking for green today... Go Leo & IPIX!

From the Innovation Website Blog.
www.ipharminc.com/new-blog/2017/7/3/growing-interest-in-novel-non-biologic-treatments-for-inflammatory-bowel-disease

CHA CHING!!!!!!!!!!!!

JUST 10-11-12

07/06/17 10:21 AM

#189002 RE: runninggirl2016 #188985

Very Nic. Thanks